Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Status:
Not yet recruiting

Trial end date:
2028-01-31

Target enrollment:

Participant gender:

Evaluate efficacy and safety of ADI-PEG 20 in patients with NASH

Phase 2

Polaris Group